Donald A Bergstrom Relay Therapeutics, Inc. (RLAY) insider trading activity

Donald A Bergstrom is President, R&D of Relay Therapeutics, Inc.. Currently has a direct ownership of 524,081 shares of RLAY, which is worth approximately $3.98 Million. The most recent transaction as insider was on Sep 02, 2022, when has been sold 4,900 shares (Common Stock) at a price of $25.46 per share, resulting in proceeds of $124,754. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 524K

0.63% 3M change

120.29% 12M change

Total Value Held $3.98 Million

Donald A Bergstrom Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 02 2022	SELL Open market or private sale	$124,754 $25.46 p/Share	4,900 Reduced 5.18%	89,659 Common Stock
Sep 02 2022	BUY Exercise of conversion of derivative security	$20,188 $4.12 p/Share	4,900 Added 4.93%	94,559 Common Stock
Sep 01 2022	SELL Open market or private sale	$186,867 $23.07 p/Share	8,100 Reduced 8.29%	89,659 Common Stock
Sep 01 2022	BUY Exercise of conversion of derivative security	$33,372 $4.12 p/Share	8,100 Added 7.65%	97,759 Common Stock
Aug 24 2022	SELL Open market or private sale	$375,000 $25.0 p/Share	15,000 Reduced 14.33%	89,659 Common Stock
Aug 24 2022	BUY Exercise of conversion of derivative security	$61,800 $4.12 p/Share	15,000 Added 12.54%	104,659 Common Stock
Aug 05 2022	SELL Open market or private sale	$160,000 $20.0 p/Share	8,000 Reduced 8.19%	89,659 Common Stock
Aug 05 2022	BUY Exercise of conversion of derivative security	$32,960 $4.12 p/Share	8,000 Added 7.57%	97,659 Common Stock
Jul 28 2022	SELL Open market or private sale	$39,030 $21.27 p/Share	1,835 Reduced 2.01%	89,659 Common Stock
Jul 06 2022	SELL Open market or private sale	$160,000 $20.0 p/Share	8,000 Reduced 8.04%	91,494 Common Stock
Jul 06 2022	BUY Exercise of conversion of derivative security	$32,960 $4.12 p/Share	8,000 Added 7.44%	99,494 Common Stock
Jun 27 2022	SELL Open market or private sale	$20,290 $20.31 p/Share	999 Reduced 1.08%	91,494 Common Stock
Jun 24 2022	SELL Open market or private sale	$160,000 $20.0 p/Share	8,000 Reduced 7.96%	92,493 Common Stock
Jun 24 2022	BUY Exercise of conversion of derivative security	$32,960 $4.12 p/Share	8,000 Added 7.37%	100,493 Common Stock
May 02 2022	SELL Open market or private sale	$320,060 $24.62 p/Share	13,000 Reduced 12.32%	92,493 Common Stock
May 02 2022	BUY Exercise of conversion of derivative security	$53,560 $4.12 p/Share	13,000 Added 10.97%	105,493 Common Stock
Apr 28 2022	SELL Open market or private sale	$46,307 $25.57 p/Share	1,811 Reduced 1.92%	92,493 Common Stock
Apr 01 2022	SELL Open market or private sale	$545,760 $30.32 p/Share	18,000 Reduced 16.03%	94,304 Common Stock
Apr 01 2022	BUY Exercise of conversion of derivative security	$74,160 $4.12 p/Share	18,000 Added 13.81%	112,304 Common Stock
Mar 29 2022	SELL Open market or private sale	$18,579 $29.87 p/Share	622 Reduced 0.66%	94,304 Common Stock
Mar 24 2022	SELL Open market or private sale	$300,000 $30.0 p/Share	10,000 Reduced 9.53%	94,926 Common Stock
Mar 24 2022	BUY Exercise of conversion of derivative security	$41,200 $4.12 p/Share	10,000 Added 8.7%	104,926 Common Stock
Mar 10 2022	SELL Open market or private sale	$250,000 $25.0 p/Share	10,000 Reduced 9.53%	94,926 Common Stock
Mar 10 2022	BUY Exercise of conversion of derivative security	$41,200 $4.12 p/Share	10,000 Added 8.7%	104,926 Common Stock
Mar 01 2022	SELL Open market or private sale	$191,040 $23.88 p/Share	8,000 Reduced 7.77%	94,926 Common Stock

Also insider at

FUSN

Fusion Pharmaceuticals Inc. Healthcare

DAB